Arca
Skip to content
Tools
Tools

Carbidopa, Levodopa, Entacapone Tablets

Recall D-0029-2026, part of FDA recall event 97768. See Rising Pharma Holdings's company page.

Rising Pharma Holding, Inc. started this Class II drug recall on Oct 7, 2025 (voluntary: firm initiated); FDA lists it as ongoing.

  • Classification: Class II
  • Started: Oct 7, 2025
  • Status: Ongoing

Why It Was Recalled

Class II

Product mix up: complaint received that sealed medication bottle contained Carbidopa, Levodopa, and Entacapone film-coated tablets (37.5 mg/150 mg/200 mg) instead of labelled lower strength Carbidopa, Levodopa, and Entacapone film-coated tablets (25 mg/100 mg/200 mg).

Record

Product
Carbidopa, Levodopa, Entacapone Tablets, 25 mg/100 mg/200 mg, 100-count bottle, Rx Only, Manufactured for: Rising Pharma Holdings, Inc. East Brunswick, NJ, 08816, Manufactured by Suven Pharmaceuticals Limited, Pashamylaram, Telangana, 205307, India. NDC# 16571-691-01
Quantity
2,064 100-count bottles
Lots and codes
Lot # CS25070, exp. date 03/31/2027
Distribution
Distributed Nationwide in the USA
Recalling firm
Rising Pharma Holding, Inc., East Brunswick, NJ, United States
How the firm notified
Letter
FDA classified
Oct 16, 2025

Rising Pharma Holding, Inc.'s Other Recalls

Newest first, one product per recall event; search them all

FDA's weekly Enforcement Report, as openFDA publishes it. A recall is classified by how likely the product is to cause harm: Class I is the most serious. openFDA drug enforcement reports

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.